Compare FRSH & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSH | TYRA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2021 | 2021 |
| Metric | FRSH | TYRA |
|---|---|---|
| Price | $9.34 | $26.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $14.86 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 12.0M | 825.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 296.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $838,809,000.00 | N/A |
| Revenue This Year | $16.30 | N/A |
| Revenue Next Year | $14.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.43 | N/A |
| 52 Week Low | $6.79 | $8.98 |
| 52 Week High | $15.51 | $40.65 |
| Indicator | FRSH | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 34.51 |
| Support Level | $7.71 | $24.88 |
| Resistance Level | $9.40 | $31.57 |
| Average True Range (ATR) | 0.43 | 1.93 |
| MACD | -0.06 | -0.41 |
| Stochastic Oscillator | 22.16 | 22.97 |
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.